Company News in the Life Science Industry

»

Reset 

Veeda Clinical Research Scores Another Perfect NPRA (Malaysian Regulatory Agency) Audit

AHMEDABAD, India, October 22, 2018 /PRNewswire/ --

Read more ››
By: PR Newswire Association LLC. - 22 Oct 2018
Related companies:  Veeda Clinical Research Pvt. Ltd

UEG Week 2018: New Research Links Crohn's Disease to Black Death

VIENNA, October 22, 2018 /PRNewswire/ --

Read more ››
By: PR Newswire Association LLC. - 22 Oct 2018

ACR 2018: Lilly Shares Updated Safety Analysis of OLUMIANT® (baricitinib) in Patients with Moderately-to-Severely Active Rheumatoid Arthritis

INDIANAPOLIS, Oct. 21, 2018 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) and Incyte Corporation (NASDAQ: INCY) announced today findings from an updated integrated safety analysis of OLUMIANT(®) (baricitinib) based on an ongoing long-term extension (LTE) study of rheumatoid arthritis (RA)... Read more ››

By: PR Newswire Association LLC. - 22 Oct 2018
Related companies:  Incyte Corporation | Eli Lilly and Company

LSK BioPharma and Jiangsu Hengrui Medicine Announce Global Clinical Collaboration to Evaluate the Combination of Anti-Angiogenesis and Immuno-Oncology Therapy for Patients with Advanced Hepatocellular Carcinoma (HCC)

SALT LAKE CITY and SHANGHAI, Oct. 21, 2018 /PRNewswire/ -- LSK BioPharma (or "LSKB"), a US-based biopharmaceutical firm and Jiangsu Hengrui Medicine, Co., Ltd. (SHA:600276, or "Hengrui"), one of the largest and most innovative fully-integrated biopharmaceutical companies based in China, today... Read more ››

By: PR Newswire Association LLC. - 22 Oct 2018
Related companies:  LSK Biopharma, Inc.

Genmab Announces Positive Topline Results in Phase III CASSIOPEIA Study of Daratumumab in Front Line Multiple Myeloma

Read more ››
By: Nasdaq / GlobenewsWire - 21 Oct 2018
Related companies:  Genmab A/S

Fujifilm Announces Entry Into U.S. Computed Tomography Market With Unveiling Of FCT Embrace At ASTRO 2018

STAMFORD, Conn., Oct. 21, 2018 /PRNewswire/ -- FUJIFILM Medical Systems U.S.A., Inc., a leading provider of diagnostic imaging and medical informatics solutions, today introduced the FCT Embrace. Powered by Analogic, the FCT Embrace... Read more ››

By: PR Newswire Association LLC. - 21 Oct 2018

Leading Lupus Scientist Recognized with Prestigious Award; Young Investigator Honored for Early Career Impact in Lupus Field

CHICAGO, Oct. 21, 2018 /PRNewswire/ -- Today, the Lupus Foundation of America recognizes two leading scientists for their remarkable contributions to lupus research at the 2018 Evelyn V. Hess Reception to be held this evening in Chicago, Ill. during the 2018 American College of Rheumatology (ACR)... Read more ››

By: PR Newswire Association LLC. - 21 Oct 2018

Loxo Oncology Announces Larotrectinib Clinical Update in Patients with TRK Fusion Cancers at the European Society for Medical Oncology 2018 Congress

Read more ››
By: Nasdaq / GlobenewsWire - 21 Oct 2018
Related companies:  Loxo Oncology, Inc.

G1 Therapeutics Presents Additional Data from Randomized Phase 2 Trial of Trilaciclib in Combination with Etoposide/Carboplatin for Treatment of First-Line Small Cell Lung Cancer

Read more ››
By: Nasdaq / GlobenewsWire - 21 Oct 2018
Related companies:  G1 Therapeutics, Inc.

BioArctic is Granted a Concept Patent in Europe for the Company's Strategy for Disease-modifying Treatment of Parkinson's Disease

STOCKHOLM, Oct. 21, 2018 /PRNewswire/ -- BioArctic AB (publ) (Nasdaq Stockholm: BIOA-B) announced today that the European Patent Office (EPO) has issued a decision to grant the company's patent application in Europe, EP09738534.8, for its Parkinson's disease concept patent. The decision states... Read more ››

By: PR Newswire Association LLC. - 21 Oct 2018
Related companies:  BioArctic AB

Daiichi Sankyo Presents Updated Results of [Fam-] Trastuzumab Deruxtecan (DS-8201) in Patients with HER2 Expressing Advanced Colorectal Cancer at 2018 European Society for Medical Oncology (ESMO) Congress

TOKYO and MUNICH and BASKING RIDGE, N.J., Oct. 21, 2018 /PRNewswire/ -- Daiichi Sankyo Company, Limited (hereafter, Daiichi Sankyo) announced that updated phase 1 safety and efficacy data for [fam-] trastuzumab deruxtecan, an investigational HER2 targeting antibody drug conjugate (ADC), were... Read more ››

By: PR Newswire Association LLC. - 21 Oct 2018

Leap Therapeutics Presents Esophagogastric Cancer Data at ESMO 2018 Annual Congress

CAMBRIDGE, Mass., Oct. 21, 2018 /PRNewswire/ -- Leap Therapeutics, Inc. (NASDAQ: LPTX) today presented clinical data from its ongoing Phase I/II study of DKN-01 in combination with Keytruda® (pembrolizumab) in patients with advanced esophagogastric cancer at the European Society for Molecular... Read more ››

By: PR Newswire Association LLC. - 21 Oct 2018
Related companies:  Leap Therapeutics

Lupus Foundation of America Studies Reveal Disparities in Care of Minority Patients and the Role of Primary Care Providers in Lupus Care Management

WASHINGTON, Oct. 21, 2018 /PRNewswire/ -- In two first of their kind research studies, the Lupus Foundation of America (LFA) has identified needs in lupus provider education and care practices for minority patients. Referral and disease management practices vary by the type of doctor a patient... Read more ››

By: PR Newswire Association LLC. - 21 Oct 2018

DxTerity Announces Presentations from Lupus and Multiple Sclerosis Studies at the 2018 ACR/ARHP Annual Meeting

LOS ANGELES, Oct. 21, 2018 /PRNewswire/ -- DxTerity, a molecular information and diagnostics company developing at-home RNA monitoring blood... Read more ››

By: PR Newswire Association LLC. - 21 Oct 2018
Related companies:  DXTERITY DIAGNOSTICS, INC.

Philips unveils new radiation oncology portfolio for a more confident path to treatment at ASTRO 2018

AMSTERDAM and SAN ANTONIO, Oct. 21, 2018 /PRNewswire/ -- Royal Philips (NYSE: PHG, AEX: PHIA), a global leader in health technology, is showcasing its new suite of radiation oncology systems and software at the Read more ››

By: PR Newswire Association LLC. - 21 Oct 2018

Varian Unveils New Bravos Afterloader System for Brachytherapy Treatments

PALO ALTO, Calif., Oct. 21, 2018 /PRNewswire/ -- Varian (NYSE: VAR) today announced the Bravos((TM) )afterloader system for High Dose Rate (HDR) brachytherapy treatments. Based on over five years of in-clinic research, Bravos is an integrated system designed to improve the patient and clinic... Read more ››

By: PR Newswire Association LLC. - 21 Oct 2018
Related companies:  Varian Medical Systems, Inc.

Varian Outlines Strategy for AI-Driven Multimodality Adaptive Radiotherapy Suite

PALO ALTO, Calif., Oct. 21, 2018 /PRNewswire/ -- During its Users Meeting at the 2018 American Society for Radiation Oncology (ASTRO) Annual Meeting, Varian (NYSE: VAR) shared details of its development work on an artificial intelligence (AI)-driven multimodality adaptive radiotherapy treatment... Read more ››

By: PR Newswire Association LLC. - 21 Oct 2018
Related companies:  Varian Medical Systems, Inc.

Samsung unveils a new ultrasound system 'HERA W10' powered by beamforming technology at ISUOG World Congress 2018

New image reconstruction architecture designed to support easier diagnosis to enhance workflow and user experience with innovative features and ergonomics

Read more ››
By: PR Newswire Association LLC. - 21 Oct 2018

Mirati Therapeutics Announces Updated Data From Ongoing Clinical Trial Of Single Agent Sitravatinib At The 2018 ESMO Congress

SAN DIEGO, Oct. 21, 2018 /PRNewswire/ -- Mirati Therapeutics, Inc. (NASDAQ: MRTX), a clinical stage targeted oncology company, today announced the completed stage 1 safety and efficacy data from the ongoing Phase 1b clinical trial of single agent sitravatinib in patients with certain classes... Read more ››

By: PR Newswire Association LLC. - 21 Oct 2018
Related companies:  MIRATI THERAPEUTICS INC.

Taiho Oncology and Servier Announce Positive Results from LONSURF® (trifluridine/tipiracil) Study Presented at ESMO 2018 Congress and Published in The Lancet Oncology

PRINCETON, N.J., Oct. 21, 2018 /PRNewswire/ -- Taiho Oncology, Inc. (U.S.), a subsidiary of Taiho Pharmaceutical Co., Ltd. (Japan) and Servier jointly announced today the clinical data from the pivotal Phase III (TAGS) trial evaluating LONSURF(®) (trifluridine/tipiracil, TAS-102) versus placebo... Read more ››

By: PR Newswire Association LLC. - 21 Oct 2018
Related companies:  Taiho Ventures, LLC
1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25 »

Explore our database of over 50,000 companies